The global cancer biomarker market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period. The major factor contributing to the growth of the market is the rising adoption of several R&D activities by the key market players along with FDA approvals across the globe For instance, in March 2021, Roche announced that the VENTANA ALK (D5F3) CDx Assay has been approved as a companion diagnostic by the US Food and Drug Administration. This assay test is the only one approved by the FDA as a companion diagnostic for LORBRENA, and it will aid in quickly identifying patients with this cancer biomarker so that they can receive more effective treatment.
Browse the full report description “Global Cancer Biomarker Market Size, Share & Trends Analysis Report by Biomarker Type (Genetic Biomarker and Protein Biomarker), By Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, and Cervical Cancer), by Application (Drug Discovery & Development, Diagnosis, Risk Assessment, and Prognostics), and by Profiling Technology (Omics Technology, Immunoassays, Cytogenetics, and Bioinformatics) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/cancer-biomarkers-market
Further, in December 2020, Thermo Fisher Scientific (US) received FDA approval NGS-based companion diagnostic for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue. In July 2020, Thermo Fisher Scientific signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., as well as an application to the Ministry of Health, Labour, and Welfare (MHLW) to expand the use of the Oncomine Dx Target Test in Japan. This agreement focuses on accelerating the local biomarker testing of NSCLC patients in Japan who are candidates for entrectinib.
Apart from this, In April 2020, Qiagen N.V. (Netherlands) Launched therascreen BRAF test as a companion diagnostic to a BRAFTOVI (encorafenib) based regimen in metastatic colorectal cancer.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Abbott Laboratories Inc., F. Hoffmann-La Roche Ltd., Merck and Co., inc., Novartis AG, and others.
Key questions addressed by the report
oDeviation from the pre-COVID-19 forecast
oMost affected region and segment
Global Healthcare BPO Market Report Segment
By Biomarker Type
By Cancer Type
By Application
By Profiling Technology
Global Healthcare BPO Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/cancer-biomarkers-market